Patents. Law. Pharma.

BLOG

Zachary Silbersher Zachary Silbersher

Can Axsome Therapeutic’s patent-thicket block Apotex’s generic Symbravo?

Axsome Therapeutics sells Symbravo (meloxicam and rizatriptan benzoate) tablets. Apotex has filed an ANDA seeking to distribute a generic version of Symbravo, and in response, Axsome has brought suit under the Hatch-Waxman Act. The rub is that Axsome has listed an enormous number of patents in the Orange Book purportedly covering Symbravo. Can Apotex litigate its way through Axsome’s patent thicket, or will consumers be deprived a lower-cost generic formulation?

Read More